C-erb B2 (Her2/neu) is neither overexpressed nor amplified in hepatic neoplasms

Applied Immunohistochemistry and Molecular Morphology

Volumn 10, Issue 3, 2002, Pages 237-241

  Vlasoff, Dmitry M ^a   Baschinsky, Dmitry Y ^a   De Young, Barry R ^a   Morrison, Carl D ^a   Nuovo, Gerard J ^a   Frankel, Wendy L ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Cirrhosis; Hepatocellular adenoma; Hepatocellular carcinoma; Her2 neu

Indexed keywords

ANTIGEN RETRIEVAL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER ADENOMA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; GENE EXPRESSION; GENETICS; LIVER TUMOR; METABOLISM; PATHOLOGY; PROTO ONCOGENE;

EPIDERMAL GROWTH FACTOR RECEPTOR 2; TUMOR MARKER;

ADENOMA, LIVER CELL; CARCINOMA, HEPATOCELLULAR; GENE AMPLIFICATION; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LIVER NEOPLASMS; PROGNOSIS; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL;

EID: 0036731936     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: 10.1097/00022744-200209000-00009     Document Type: Article

References (33)

1. Hepatocellular carcinoma
2. Hepatic segmentectomy for curative resection of primary hepatocellular carcinoma
3. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma: Results of long-term follow-up
4. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma
5. Clinicopathologic features and prognosis of resected hepatocellular carcinomas of varied sizes with special reference to proliferating cell nuclear antigen
6. Prognostic significance of proliferating cell nuclear antigen expression in hepatocellular carcinoma
7. Expression of Ki-67 antigen in hepatocellular carcinoma using monoclonal antibody MIB1: A comparison with proliferating cell nuclear antigen
8. Prognostic significance of nucleolar organizer regions in hepatocellular carcinoma
9. Flow cytometric analysis of the nuclear DNA content of hepatocellular carcinoma
10. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: A clinicopathological correlation
11. Androgen and oestrogen receptors in hepatocellular carcinoma and surrounding liver parenchyma: Impact on intrahepatic recurrence after hepatic resection
12. The neu oncogene encodes an epidermal growth factor receptor-related protein
13. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
14. Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene
15. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
16. Studies of the Her/neu proto-oncogene in human breast and ovarian cancer
17. The prognostic value of c-erb B2 in primary breast carcinomas: A study on 942 cases
18. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: Poor prognosis in node-negative breast carcinomas
19. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: Evaluation of the prognostic value in a Cox proportional hazards multiple regression
20. Amplification and overexpression of HER-2/neu in carcinoma of the salivary gland: Correlation with poor prognosis
21. Expression of c-erb B family gene products in adenoid cystic carcinoma of salivary glands: An immunohistochemical study
22. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer
23. Determination of the oncogenes p53 and C-erb B2 in the tumor cytosols of advanced hepatocellular carcinoma (HCC) and correlation to survival time
24. Natural history of hepatocellular carcinoma and prognosis in relation to treatment: Study of 850 patients
25. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system
26. Prognosis of hepatocellular carcinoma: The BCLC staging classification
27. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies
28. Her-2/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridization
29. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma
30. C-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma
31. C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: An immunohistochemical study
32. Immunoreactivity for c-erbB-2 oncopeptide in benign and malignant diseases of the liver
33. The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials